The short answer on KPV peptide
KPV is a three-amino-acid fragment of alpha-melanocyte-stimulating hormone, studied mainly in cells and animals. Researchers have mapped how it enters cells and dampens inflammatory signalling. No completed human trial of KPV has been published. Its mechanism is well described, but its effects in people remain unproven.
*Last updated 18 October 2026. Prepared by the PrimeTime BioLabs editorial team. Sources checked for this review include primary literature indexed in PubMed and PubMed Central, FDA advisory-committee materials, and the PubChem and CAS chemical registries. A named medical reviewer has not yet been assigned to this article.*
Six things the KPV evidence supports
- KPV is a synthetic tripeptide, Lys-Pro-Val, matching residues 11 to 13 of alpha-MSH.
- Research shows KPV entering cells through the PepT1 transporter and interrupting NF-kB signalling.
- Every efficacy finding comes from cell culture or animal work, and no completed human trial exists.
- Animal tolerability is not human safety, and long-term exposure has never been studied in any species.
- An FDA advisory panel recommended KPV in July 2026, yet the 503A Bulks List has not changed.
- A described mechanism is not a demonstrated treatment, and KPV has not crossed that line.
KPV at a glance
- Name — KPV
- Also written — Lys-Pro-Val, alpha-MSH (11-13)
- Sequence — H-Lys-Pro-Val-OH
- Molecular formula — C16H30N4O4
- Molecular weight — 342.43 g/mol (free peptide)
- Monoisotopic mass — 342.2267 Da
- CAS number — 67727-97-3
- PubChem CID — 125672
- Strength supplied — 10 mg lyophilised vial
- Category — Recovery Peptides
- Research evidence status — Cell culture and animal models only
- Human approval status — Not FDA-approved, no completed human trials
These are identity and catalogue facts. They describe what the vial contains. None of them says anything about whether KPV works, and none of them makes it suitable for human use. The KPV 10 mg product page carries the current listing.
What KPV actually is
Alpha-MSH is a hormone thirteen amino acids long, running Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val. KPV is the last three residues of that chain, and nothing else.
KPV is a synthetic tripeptide (lysine-proline-valine) matching the C-terminal fragment (residues 11–13) of alpha-melanocyte-stimulating hormone (α-MSH). Studied in laboratory and animal models of inflammation, it enters cells via the PepT1 transporter and is researched for NF-kB signaling effects. It is not FDA-approved and has no completed human trials as of October 2026.
Two pieces of terminology carry most of the weight in the research that follows.
PepT1 is a transporter protein that moves di-peptides and tri-peptides across cell membranes, mostly in the intestine. It is the route by which KPV appears to get inside cells.
NF-kB is the signalling pathway that drives inflammatory output. When it activates, cells produce inflammatory messengers called cytokines, and blocking it reduces that output. Most anti-inflammatory research on KPV measures some version of this.
One more point of identity matters later. The region of alpha-MSH that binds melanocortin receptors is the motif His-Phe-Arg-Trp, sitting at residues 6 to 9. KPV is residues 11 to 13. That motif is simply absent from the molecule.
How KPV gets into a cell and what it does there
Most explanations of KPV stop at the phrase "it reduces inflammation." The published research is more specific, and that specificity is what separates KPV from a generic anti-inflammatory claim.
How KPV gets inside a cell
Guillaume Dalmasso and colleagues published the foundational work in Gastroenterology in 2008. They showed that PepT1 carries KPV into intestinal epithelial cells and immune cells. PepT1 normally moves small peptide fragments left over from digested food.
PepT1 sits at low levels in the healthy colon. It is upregulated during inflammatory bowel disease. The consequence is unusual and worth stating plainly. Inflamed tissue expresses more of the transporter, so inflamed tissue takes up more of the peptide.
*Evidence category: human cell culture and animal in vivo.*
What KPV does after uptake
The same 2008 study found that nanomolar concentrations of KPV inhibited NF-kB and MAP kinase signalling. Pro-inflammatory cytokine secretion fell alongside it. Nanomolar is a very low concentration, which is part of why the result drew attention.
Stephen Land took the mechanism further in 2012, working in human bronchial epithelial cells. KPV appeared to block the nuclear import of p65RelA, one component of the NF-kB complex. The proposed route was interference at the importin-alpha binding site on that protein.
That detail matters twice over, for reasons worth separating. It describes a specific molecular interaction, not a vague signalling effect. It also appears almost nowhere in the popular writing about KPV.
Land's study included a useful internal contrast. Gamma-MSH suppressed inflammation in the same cells, but its effect required the MC3R melanocortin receptor. The KPV effect proceeded without that receptor.
*Evidence category: human cell culture.*
Whether KPV uses melanocortin receptors
KPV comes from a hormone that works through melanocortin receptors. The natural assumption is that the fragment works the same way. Several lines of evidence argue against that assumption.
Stephen Getting and colleagues reported in 2003 that KPV kept its anti-inflammatory effect in mice carrying a non-functional MC1R. These are the recessive yellow e/e mice. A melanocortin MC3 and MC4 antagonist failed to block the KPV effect. KPV also did not raise cAMP the way core melanocortin peptides did.
Klaus Kannengiesser and colleagues reached a similar conclusion in 2008. In MC1R-deficient mice given DSS colitis, KPV treatment rescued every animal in the treated group from death. Their published wording stayed careful, reporting that the effects appear at least partially independent of MC1R signalling.
The case is strong, though it is not airtight.
Richard Elliott and colleagues reported in 2004 that KPV raised intracellular calcium in cells transfected with the MC1 receptor. No cAMP rise appeared in keratinocytes. Some interaction with melanocortin receptors cannot be excluded on that evidence.
A third route has also been proposed. Vincenza Bonfiglio and colleagues found in 2006 that L-NAME, a nitric oxide synthase inhibitor, blunted KPV's effect on corneal wound healing in rabbits. Nitric oxide may play a part that receptor experiments would not capture.
The honest summary is narrow on this point. The dominant anti-inflammatory effect does not appear to need melanocortin receptors. Whether KPV touches them at all remains unresolved.
*Evidence category: animal in vivo and human cell culture.*
Four claims about KPV that are not interchangeable
Research discussion blurs these constantly, so they are worth separating.
- Transporter-mediated uptake means KPV gets inside a cell.
- A signalling change means a measured pathway shifts.
- A receptor hypothesis is a proposal about which switch is involved.
- A human outcome means a person measurably improved.
KPV has evidence for the first two. It has an active dispute over the third. It has nothing at all for the fourth.
What KPV has actually been tested on
Each research strand below names the model, the measured outcome, and the limitation that caps it.
What the gut models measured
Gut inflammation is the most heavily studied area, and the animal results broadly agree.
Dalmasso's 2008 work gave KPV orally, in drinking water. It reported reduced incidence of colitis induced by both DSS and TNBS in mice. Pro-inflammatory cytokine expression fell with it.
Kannengiesser's 2008 study ran two colitis models. Treated animals recovered earlier, regained more body weight, and showed less inflammatory infiltrate. Myeloperoxidase activity in colon tissue dropped significantly.
Emilie Viennois and colleagues added the most useful control in 2016. KPV reduced tumour formation in a mouse model of colitis-associated cancer. In PepT1-knockout animals, that effect disappeared entirely. Removing the transporter removed the benefit. That control is what makes the PepT1 claim load-bearing.
One caveat applies across much of this literature. A large share of later studies test KPV inside an engineered delivery vehicle. Bo Xiao and colleagues reported in 2017 on KPV loaded into hyaluronic-acid nanoparticles, delivered orally inside a hydrogel. That system improved mucosal healing in a mouse colitis model. The authors attributed part of the result to targeted delivery into colonic epithelial cells and macrophages.
The engineering is the point of those studies. A nanoparticle protects the peptide, concentrates it at inflamed tissue, and changes how much reaches a cell. Results from a stabilised preparation do not transfer automatically to raw peptide in a vial.
*Evidence category: animal in vivo. No human efficacy data exist.*
What the skin research found
Here the record contains something most KPV articles leave out.
Kasturi Pawar and colleagues measured how well KPV crosses human skin in 2017. By simple passive diffusion, permeation across dermatomed human skin fell below the assay detection limit of 0.01 micrograms per millilitre. Measurable delivery required active assistance, specifically iontophoresis, microneedles, or both together.
Anyone assessing a topical KPV preparation should weigh that result carefully. Intact skin appears to be a serious barrier to this molecule.
Weifeng Shao and colleagues reported in 2021 on a KPV-loaded mucoadhesive hydrogel. It improved tissue repair and lowered IL-1beta and TNF-alpha in rats with chemotherapy-induced oral mucositis. Mucosal tissue is not the same barrier as skin, so the two findings do not cancel out.
For a copper-peptide comparison on skin research, our GHK-Cu article covers that evidence base separately.
*Evidence category: human tissue ex vivo and animal in vivo.*
Why the antimicrobial picture conflicts
Antimicrobial activity is often presented as settled. The published record disagrees with itself.
M. Cutuli and colleagues reported in 2000 that alpha-MSH and KPV inhibited colony formation by Staphylococcus aureus. The same work reported reduced viability and germ-tube formation in Candida albicans, across a broad concentration range.
Abigael Songok and colleagues reported a null result in 2018. Antimicrobial assays run under a variety of conditions showed no activity for the compound they tested. Their molecule was an acetylated and amidated analogue, Ac-KPV-NH2, which is not identical to the free peptide.
That distinction keeps the 2018 paper from being a direct refutation. It does not make the question settled. Articles presenting KPV antimicrobial activity as established are overstating the record.
*Evidence category: human cell culture, conflicting.*
What the cornea study adds
Bonfiglio's 2006 rabbit study sits outside the gut and skin strands. Topical KPV produced complete corneal re-epithelialisation in eight of eight treated eyes at sixty hours. None of the placebo corneas had re-epithelialised at that point.
The effect was inhibited by L-NAME, which implicates nitric oxide. This is a topical animal model with a small group, so it suggests a mechanism and nothing more.
*Evidence category: animal in vivo.*
Why MCAS interest is running ahead of the evidence
Search interest in KPV for mast cell activation syndrome has climbed sharply. The evidence behind that interest deserves a plain description.
No human trial has tested KPV for MCAS or histamine intolerance. No published animal model of MCAS has tested KPV either. The gap is not a matter of weak data. There is no controlled data of any kind.
What exists is a mechanistic argument. A compound that dampens NF-kB signalling might plausibly affect mast-cell-driven inflammation. Alongside that argument sit self-reported accounts from people describing their own experiences.
Plausibility is a reason to run a study, and not a result in itself. Self-reported accounts record what someone believes happened, with no control group and no measurement.
The gap also runs deeper than missing human trials. Mast cell activation syndrome is itself a contested diagnosis. Afrin and colleagues documented two competing sets of diagnostic criteria in 2020, labelled consensus-1 and consensus-2. The two disagree substantially on how many patients qualify for the diagnosis. Testing any compound against MCAS first requires agreement on what is being measured.
Readers should treat the MCAS question as open and untested. Interest in a topic is not evidence about it.
*Evidence category: no controlled evidence.*
KPV and BPC-157 compared on evidence, not outcomes
These two come up together constantly. The comparison below sticks to evidence categories and research context, because no fair ranking of outcomes is possible.
- Size — KPV: Three amino acids — BPC-157: Fifteen amino acids
- Origin — KPV: Fragment of alpha-MSH, a human hormone — BPC-157: Sequence described in human gastric juice
- Uptake route — KPV: PepT1 transporter, with knockout confirmation — BPC-157: No comparably specific route described
- Main research focus — KPV: Inflammatory signalling, gut models — BPC-157: Tissue repair, tendon, muscle, gut
- Literature size — KPV: Small and narrow — BPC-157: Substantially larger
- Mechanism detail — KPV: High, down to p65RelA nuclear import — BPC-157: Broader, less molecularly specific
- Completed human efficacy trials — KPV: None published — BPC-157: None published
- July 2026 PCAC outcome — KPV: Recommended, wound healing and inflammatory conditions — BPC-157: Recommended, ulcerative colitis
- Category 2 removal — KPV: 22 April 2026 — BPC-157: 22 April 2026
One gap in that table deserves emphasis. No study has tested KPV against BPC-157 directly. Every comparison, including this one, lines up two separate literatures and reasons across the gap between them. Our BPC-157 explainer covers that compound's evidence in full.
TB-500 belongs in a different conversation. It is a seven-amino-acid fragment studied for actin binding and cell migration, which places it in tissue-repair research. KPV by contrast sits in inflammatory-signalling research. They are not substitutes in any published model, and our TB-500 article covers that distinction.
Where KPV sits in the KLOW blend
KPV appears as one component of KLOW, the GLOW-plus-KPV blend. PrimeTime BioLabs does not publish a per-component quantity split for it. Our KLOW article handles the blend in detail, including what its certificate of analysis can and cannot tell you.
What the safety record can and cannot establish
Animal studies have generally described KPV as well tolerated at the exposures tested. That sentence carries far less weight than it appears to.
Model tolerability does not establish human safety. Species differ in metabolism, immune response and sensitivity. A result in a mouse given a peptide in drinking water says little about a person.
Long-term exposure has not been studied in any species over meaningful durations. The published work runs for days or weeks, matched to the length of an induced-colitis model.
The regulatory record says the same thing in blunter terms. Ahead of the July 2026 meeting, FDA's own scientific review team proposed that KPV not be added to the 503A Bulks List. Its briefing materials concluded that the characterisation, effectiveness and safety evidence was insufficient for the nominated uses.
No published human side-effect profile exists, because no completed human trial exists. Any side-effect list presented as applying to people is not derived from evidence about people.
Two further unknowns deserve naming here. Immunogenicity has not been characterised, which matters for any peptide intended to enter a body repeatedly. Interactions with other compounds have not been studied either, so no claim about combining KPV with anything else rests on evidence.
One distinction is worth holding onto. An absence of reported harm is not a finding of safety. Nobody has looked in the setting that would produce such reports. The accurate statement is that human safety is unknown, which differs from safe.
*Evidence category: animal in vivo and regulatory record.*
Why this article gives no KPV dosage
Dosage is the most searched question about KPV. This article will not answer it, and the reason is not caution for its own sake.
No established human dose for KPV exists. Establishing one requires completed human trials, dose-ranging work and safety thresholds. None of that has been published.
Protocols circulating online are extrapolations, not findings. Some are scaled from animal studies and some come from community practice, and neither source can support a human recommendation. Published animal work used routes and exposures chosen to suit the model, not to suit a person.
KPV is supplied for laboratory research use only. This article therefore contains no dosing, reconstitution, administration, timing, cycling or stacking guidance, and none should be inferred from anything written above or below.
Mechanistic complementarity between two peptides is sometimes offered as a reason to combine them. That reasoning does not establish the safety or the effectiveness of any combination.
Where KPV stands with the FDA right now
The regulatory position moved twice in 2026, and both moves are widely misreported.
2023. FDA placed a group of peptides, KPV among them, into Category 2 of its 503A bulk drug substances list. That category covers substances which may present significant safety risks in compounding.
22 April 2026. KPV came off Category 2, following an announcement earlier that month. The removal followed withdrawal of the underlying nominations. It did not reflect a new safety determination. Coming off Category 2 placed KPV on no list at all. It did not move to the 503A Bulks List, and it did not enter Category 1, where enforcement discretion applies.
23 and 24 July 2026. The Pharmacy Compounding Advisory Committee reviewed seven peptides. For KPV, evaluated for wound healing and inflammatory conditions, the committee voted in favour of recommending inclusion on the 503A Bulks List.
The reported tally was eight in favour, six against, with one abstention. That figure comes from meeting reporting by the law firm Bass, Berry & Sims. Restore Health Consulting reported the same tally, and states it verified counts against FDA's archived meeting livestream. FDA did not publish official vote counts in its own public materials. The number should be read as reported, not as an official FDA result.
The committee voted against the recommendation of FDA's own scientific review staff, who had proposed adding none of the seven.
Today. The vote is advisory and non-binding. FDA has not completed the rulemaking required to add KPV to the 503A Bulks List, and the agency is not obliged to adopt the recommendation. An advisory recommendation is not approval, not final rulemaking, and not legal authorisation.
A further PCAC meeting is expected before the end of February 2027. That session covers GHK-Cu, Melanotan II, LL-37, dihexa acetate and PEG-MGF. KPV is not on its published agenda, and the meeting had not been scheduled or docketed at the time of this review.
This status is time-sensitive and was verified on 18 October 2026. Our guide to peptide legality covers the wider category system.
*Evidence category: regulatory record.*
What a KPV certificate of analysis should show
A certificate of analysis describes the material in the vial. It does not establish safety, efficacy, or fitness for any use in people. Read within that limit, it is the most useful document a research buyer receives.
Our guide to reading a peptide certificate of analysis covers the general method. The checks below are specific to KPV.
- Mass spectrometry identity. The observed mass should correspond to 342.43 g/mol for the free peptide. A monoisotopic figure near 342.2267 Da serves the same purpose.
- Stated form. The certificate should say whether the material is the free peptide or an acetate salt. Commercial peptide is often supplied as an acetate salt, and acetate content changes peptide mass per vial.
- HPLC purity with its method. Look for the actual percentage and the chromatogram behind it, not a figure repeated from marketing copy.
- Batch number matching. The lot on the certificate must match the lot printed on the vial received.
- Analysis date. An undated certificate, or one predating the batch, says nothing about the material in hand.
- Secondary peaks. Stability work on KPV identifies lys-pro-diketopiperazine as the major degradation product under acid, alkali and oxidative stress. Unexplained secondary peaks are worth a question.
That last check is KPV-specific chemistry, and it is the kind of detail a generic certificate guide cannot supply. Storage conditions interact with it, and our storage guide covers what the published evidence does and does not establish there.
*Evidence category: analytical chemistry.*
The bottom line on KPV peptide
KPV is unusually well characterised for a molecule its size, and unusually untested for one discussed so widely. The PepT1 and NF-kB account is specific, reproducible and supported by a knockout control. The gut models agree with each other. The p65RelA detail gives the mechanism a precision most peptide claims never reach.
Then the evidence stops. Human skin barely admits the molecule by passive diffusion. The antimicrobial literature argues with itself. The MCAS question has no controlled data at all. No human trial of any size has been completed, so nothing is known about what KPV does in people.
The July 2026 advisory vote changed the conversation without changing the rules. Reading it as approval would be a straightforward error.
For researchers working within those limits, the KPV 10 mg vial is supplied for laboratory use only. The product listing states that each lot is third-party tested and that a lot-specific certificate is available after purchase.
